)
Glenmark Pharmaceuticals today said its novel monoclonal antibody for potential treatment of chronic pain is entering human trials.
The company has completed preclinical studies and Phase 1 enabling preclinical development programme for GBR 900; it has filed a Phase I clinical trial application with the MHRA, UK, Glenmark Pharma said in a BSE filing.
GBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).
The company said this is the first anti-TrkA monoclonal antibody to enter clinical development.
Glenmark Pharmaceuticals Ltd President of Biologics and Chief Scientific Officer Michael Buschle said: "We are very excited about the Phase I clinical study starting and expect that this study will extend the preclinical differentiation into a drug which will be clinically differentiated from anti-NGF antibodies.
